SynthesisLipids in health and disease2022
Diagnostic accuracy of the visceral adiposity index in patients with metabolic-associated fatty liver disease: a meta-analysis.
Synthesis in Lipids in health and disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.
- Diagnostic value of visceral adiposity index in chronic kidney disease: a meta-analysis.Acta diabetologica · 2023Pooled it
- Associations between adiposity indices and liver steatosis and stiffness assessed by two-dimensional shear wave elastography in patients with type 2 diabetes mellitus: a cross-sectional study.BMC endocrine disorders · 2026Article
- Predicting MASLD in People With HIV Using Anthropometric Measures: A Multicenter Cross-Sectional Study.Open forum infectious diseases · 2026Article
- The Visceral Adiposity Index and Its Usefulness in the Prediction of Cardiometabolic Disorders.Nutrients · 2025Review
- Use of Metabolic Scores and Lipid Ratios to Predict Metabolic Dysfunction-Associated Steatotic Liver Disease Onset in Patients with Inflammatory Bowel Diseases.Journal of clinical medicine · 2025Article
- Establishment and Evaluation of a Noninvasive Metabolism-Related Fatty Liver Screening and Dynamic Monitoring Model: Cross-Sectional Study.Interactive journal of medical research · 2024Article
- The Different Predictive Effects of Multiple Body Fat Indexes on Metabolic Dysfunction-Associated Fatty Liver Disease.Diabetes, metabolic syndrome and obesity : targets and therapy · 2024Article
- Association between Chinese visceral adiposity index and metabolic-associated fatty liver disease in Chinese adults with type 2 diabetes mellitus.Frontiers in endocrinology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
backgroundConflicting results on the prognostic value of the visceral adiposity index (VAI) in patients with metabolic-associated fatty liver disease (MAFLD) have been reported. This study aimed to assess the diagnostic value of the VAI in MAFLD patients.
methodsThe Cochrane Library, PubMed, Embase, and other databases were searched to collect all documents that met the inclusion criteria from the establishment of the database to September 2021. The methodological quality of the included studies was assessed using the Newcastle-Ottawa Scale. The heterogeneity among the studies was analysed by the Cochran Q test and I
resultsA total of 9 studies were included. The overall quality of the included studies was good. Meta-analysis showed that the combined sensitivity of the VAI for the diagnosis of MAFLD was 0.70 [95% CI (0.69-0.71)], the combined specificity was 0.67 [95% CI (0.67-0.68)], the combined positive likelihood ratio was 2.08 [95% CI (1.87-2.31)], the combined negative likelihood ratio was 0.39 [95% CI (0.34-0.44)], and the combined diagnostic odds ratio was 5.81 [95% CI (4.73-7.14)]. The corresponding area under the curve was 0.79 [95% CI (0.75-0.82)]. Meta-regression analysis showed that the diagnostic method was a potential source of heterogeneity (P < 0.05). The Fagan diagram showed that the precision of MAFLD diagnosis was 70% when the pretest probability was set to 50% and then supplemented by the VAI.
conclusionsThe VAI is an independent predictor in the diagnosis of MAFLD and may be helpful in the detection of MAFLD. A VAI > 2.33 suggests that patients have a high probability of having MAFLD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.